20776-51-6

Basic information

• Product Name: 2-AMINO-3-BROMOBENZOIC ACID
• Synonyms: 2-AMino-3-broMobenzoic acid, 95+%;3-Bromoanthralic acid, 2-Bromo-6-carboxyaniline;Benzoic acid, 2-amino-3-bromo-;2-AMINO-3-BROMOBENZOIC ACID;AURORA KA-6184;BUTTPARK 49\07-48;2-Amino-3-bromobenzoic acid 97%;3-Bromoanthralic acid
• CAS NO: 20776-51-6
• Molecular Formula: C₇H₆BrNO₂
• Molecular Weight: 216.03
• EINECS: 1533716-785-6
• Product Categories: Chemical Synthesis;New Products for Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Benzoic acid;Carboxylic Acids;Phenyls & Phenyl-Het;Amines;Building Blocks;C7
• Mol File: 20776-51-6.mol

Chemical Properties

• Melting Point: 173 °C
• Boiling Point: 343.5 °C at 760 mmHg
• Flash Point: 161°C
• Appearance: White to pale yellow/Solid
• Density: 1.793 g/cm³
• Vapor Pressure: 2.68E-05mmHg at 25°C
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 4.55±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-3-BROMOBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-3-BROMOBENZOIC ACID(20776-51-6)
• EPA Substance Registry System: 2-AMINO-3-BROMOBENZOIC ACID(20776-51-6)

Safety Data

• Hazard Codes: Xi,Xn,T
• Statements: 22-36/37/38-25
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 20776-51-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-3-bromobenzoic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to serve as a building block in the development of new medications, particularly those targeting specific biological pathways or receptors.
Used in Chemical Synthesis:
2-Amino-3-bromobenzoic acid is also utilized in chemical synthesis for creating a range of compounds with different applications. Its versatility in chemical reactions makes it a valuable component in the production of various chemical products, including those used in the pharmaceutical, agrochemical, and materials science industries.
Used in Research and Development:
Due to its unique structure and properties, 2-Amino-3-bromobenzoic acid is often employed in research and development settings. Scientists and researchers use it to study various biological and chemical processes, as well as to develop new methods and techniques for synthesizing complex molecules.

InChI:InChI=1/C7H6BrNO2/c8-5-3-1-2-4(6(5)9)7(10)11/h1-3H,9H2,(H,10,11)/p-1

Upstream product

• 7647-01-0 hydrogenchloride 
• 116529-61-4 3-bromo-2-nitrobenzoic acid 
• 91-56-5 indole-2,3-dione 
• 118-92-3 anthranilic acid 
• 101080-38-0 N-(2-bromophenyl)-2-isonitrosoacetanilide 
• 615-36-1 2-bromoaniline 
• 104670-74-8 methyl 2-amino-3-bromobenzoate 
• 101080-38-0 N-(2-bromo-phenyl)-2-[(E)-hydroxyimino]acetamine 
• 89-52-1 o-acetylamino-benzoic acid 
• 861791-77-7 2-acetylamino-3-bromo-benzoic acid 
• 20780-74-9 7-bromoisatin 

Downstream Products

• 21192-04-1 1-Brom-triptycen 
• 1263413-81-5 8-bromo-2,3-dimethyl-3H-quinazolin-4-one 
• 221298-75-5 2-methyl-4-chloro-8-bromo-quinazoline 
• 1268520-96-2 C₁₀H₉N₃O₂ 
• 1410974-28-5 3-bromo-2-(2-methoxyacetamido)-N-methylbenzamide 
• 1508303-94-3 3-bromo-2-[(1-isobutyl-1H-imidazo[4,5-c]quinolin-4-yl)amino]benzoic acid 
• 121772-84-7 methyl 2-iodo-3-bromobenzoic acid 
• 1261653-43-3 methyl 3-bromo-2-cyanobenzoate 

Relevant articles and documents

COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME

The present invention discloses an organic compound and an organic electroluminescence device using the organic compound as a material in the light emitting layer of the organic electroluminescence device. The organic compound may be for lowering a driving voltage, power consumption or increasing a current efficiency or 90% life time of the organic electroluminescence device. The same definition as described in the present invention.

Bicyclic heteroaryl compound with PAR4 antagonistic activity and application thereof

The invention discloses a bicyclic heteroaryl compound with PAR4 antagonistic activity and application thereof. The invention provides the bicyclic heteroaryl compound with PAR4 antagonistic activity,and the bicyclic heteroaryl compound has remarkable antagonistic activity on PAR4 in an in-vitro anti-platelet aggregation experiment, so that platelet aggregation is effectively inhibited, and the bicyclic heteroaryl compound can be used for preparing medicines for preventing or treating various thromboembolic diseases.

Br?nsted Acid-Catalyzed Asymmetric Ring-Closing Alkylation of Inert N-substituted Pyrroles with α, β-Unsaturated Ketones

A Chiral Br?nsted acid catalyzed asymmetric intramolecular ring-closing alkylation of inert pyrroles with α, β-unsaturated ketones has been developed. This approach gave a wide range of 4-phenyl-4,5-dihydro-6H-benzo[f]pyrrolo[1,2-a]azepin-6-ones in high yields with good enantioselectivities under mild reaction conditions. (Figure presented.).

Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent IKur Inhibitor

A new series of phenylquinazoline inhibitors of Kv 1.5 is disclosed. The series was optimized for Kv 1.5 potency, selectivity versus hERG, pharmacokinetic exposure, and pharmacodynamic potency. 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (13k) was identified as a potent and ion channel selective inhibitor with robust efficacy in the preclinical rat ventricular effective refractory period (VERP) model and the rabbit atrial effective refractory period (AERP) model.

PYRIMIDO-DIAZEPINONE COMPOUND

Provided are a compound represented by general formula (I), or the pharmaceutically acceptable salt thereof, (wherein Ra represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom, optionally substituted lower alkyl or cycloalkyl, or R1 and R2 are combined together with the adjacent nitrogen atom thereto to form nitrogen-containing heterocyclic group, and Z represents a bicyclic heterocyclic group in which optionally substituted two six-membered rings are fused to each other, or the like) and the like.

A High-Throughput Assay for Arylamine Halogenation Based on a Peroxidase-Mediated Quinone-Amine Coupling with Applications in the Screening of Enzymatic Halogenations

Arylhalides are important building blocks in many fine chemicals, pharmaceuticals and agrochemicals, and there has been increasing interest in the development of more "green" halogenation methods based on enzyme catalysis. However, the screening and development of new enzymes for biohalogenation has been hampered by a lack of high-throughput screening methods. Described herein is the development of a colorimetric assay for detecting both chemical and enzymatic arylamine halogenation reactions in an aqueous environment. The assay is based on the unique UV/Vis spectrum created by the formation of an ortho-benzoquinone-amine adduct, which is produced by the peroxidase-catalysed benzoquinone generation, followed by Michael addition of either a halogenated or non-halogenated arylamine. This assay is sensitive, rapid and amenable to high-throughput screening platforms. We have also shown this assay to be easily coupled to a flavin-dependent halogenase, which currently lacks any convenient colorimetric assay, in a "one-pot" workflow.

Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors

Intra-molecular hydrogen bonding was introduced to the quinazoline motif to form a pseudo ring (intra-molecular H-bond scaffold, iMHBS) to mimic our previous published core structures, pyrido[2.3-D]pyrimidin-7-one and pteridinone, as PI3K/mTOR dual inhibitors. This design results in potent PI3K/mTOR dual inhibitors and the purposed intra-molecular hydrogen bonding structure is well supported by co-crystal structure in PI3Kγ enzyme. In addition, a novel synthetic route was developed for these analogs.

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

Alpha-helical mimetics

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

Novel bromination method for anilines and anisoles using NH 4Br/H2O2 in CH3COOH

A simple, efficient, regioselective, environmentally safe, and economical method for the oxybromination of anilines and anisoles without catalyst is reported. The electrophilic substitution of bromine generated in situ from ammonium bromide as a bromine source and hydrogen peroxide as an oxidant for the first time.